Thursday, September 24, 2026
1:00 p.m. – 2:00 p.m. ET
Please note this TeleECHO program is 1:00 p.m. Eastern, 12:00 p.m. Central, 11:00 a.m. Mountain and 10:00 a.m. Pacific.
PRESENTING FACULTY
 |
Premal H. Thaker, M.D. David & Lynn Mutch Distinguished Professor of Obstetrics & Gynecology Chief of Gynecologic Oncology Director of Gynecologic Oncology Clinical Research Professor in Gynecologic Oncology Washington University School of Medicine St. Louis, Missouri |
PROGRAM OVERVIEW
The proposed educational activities will be designed to meet the educational needs of gynecologic oncologists, community oncologists, advanced healthcare practitioners, nurses, pharmacists, pathologists who care for patients with endometrial cancer (EC). We aim to help clinicians better: apply predictive biomarkers to develop guideline-informed treatment plans for patients with recurrent or advanced EC; incorporate clinical trial data and AE management for approved and emerging immunotherapy for recurrent or advanced EC to improve treatment outcomes; and integrate strategies for shared decision making and multidisciplinary care for patients with recurrent or advanced EC.
TARGET AUDIENCE
This activity is designed to meet the educational needs of gynecologic oncologists, community oncologists, advanced healthcare practitioners, nurses, pharmacists, pathologists who care for patients with endometrial cancer (EC).
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Apply predictive biomarkers to develop guideline-informed treatment plans for patients with recurrent or advanced EC
- Incorporate clinical trial data and AE management for approved and emerging immunotherapy for recurrent or advanced EC to improve treatment outcomes
- Integrate strategies for shared decision making and multidisciplinary care for patients with recurrent or advanced EC
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
ACCME INNOVATION PARTNER
Med Learning Group (MLG) is proud to be recognized as an ACCME Innovation Partner, leading the way in simplifying CME for physicians. As an Innovation Partner, MLG will be working with the ACCME by submitting credits directly to CME Passport.
PHYSICIAN DISCLAIMER: Upon your acceptance in the evaluation and completion of this CME activity, Med Learning Group will share your completion information and certain personal details (e.g., name, National Provider Identifier, birthdate MM/DD) with the ACCME for inclusion in your CME Passport transcript and, as applicable, reporting to certifying, licensing, or other regulatory authorities that you specify.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs (eg, dietary, physical, etc). Please contact Med Learning Group prior to participating at [email protected]
